Facebook Twitter YouTube Google Plus

National Mesothelioma Virtual Bank

Michael Becich, MD, Ph D
University of Pittsburgh School of Medicine

Michael Becich, MD, PhD, is a professor and chair of the Department of Biomedical Informatics at the University of Pittsburgh School of Medicine. Becich, who also is a professor of pathology, of information services/telecommunications and clinical/translational sciences, has research interests in translational bioinformatics, pathology informatics, oncology informatics and tissue banking informatics. He is principal investigator or plays major roles in a number of large grants from the National Institutes of Health (NIH) and other funding entities. Some of these grant studies focus on: clinical and translational bioinformatics; expansion of the National Mesothelioma Virtual Registry and Tissue Bank; and skin cancer, for which he is a core director for a Specialized Program of Research Excellence (SPORE) grant from the NIH. In addition, Becich is associate director of the University of Pittsburgh Clinical and Translational Research Institute and the University of Pittsburgh Cancer Institute. He earned his MD and PhD in medicine and experimental pathology at Northwestern University, was a resident in anatomic pathology at Washington University in St. Louis, and completed fellowships in pathology at the University of Nebraska and in experimental cell biology at Washington University.

To view the video, click on it.

Experimental Strategies in Peritoneal Mesothelioma

Experimental Strategies in Malignant Mesothelioma

Raising the Bar in Mesothelioma Research

Discovery / Progress - Mesothelioma Research and the Dept. of Defense (DoD)

Palliative Care is Not a Dirty Word

National Mesothelioma Virtual Bank

Mesothelioma Legal Panel

Mesothelioma Genetics Project

Making the Case for Federal Funding for Mesothelioma - Briefing on Capitol Hill

Government Benefits: Know Your Options

Global Perspectives in Malignant Mesothelioma

Finding Spiritual Support

Updates on Clinical Trials and Standard Therapies

Q&A Panel - Experimental Strategies in Malignant Mesothelioma

Words: Friend or Foe

Complementary and Alternative Medicine Approaches

Advocacy 101

Advancing the Mesothelioma Mission